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EXECUTIVE SUMMARY 
 
This report presents the findings of a study to elicit societal preferences and weights for 
Quality Adjusted Life Year (QALY) gains across three characteristics: 1) Burden of illness 
(BOI) from a medical condition given current health care interventions – defined as the 
QALY loss per patient from a condition due to premature mortality and/or reduced health-
related quality of life (HRQOL) measured against life expectancy and health-related quality 
of life without the condition; 2) Therapeutic improvement (TI) - whether preferences for large 
QALY gains are disproportionately larger than the size of the gain (e.g. weight a QALY gain 
of 2 more than 4 times a QALY gain of 0.5) and 3) End of life (EOL) - defined by NICE as 
expected survival of less than 2 years and expected survival gain of 3 months or more. 
 
Methods 
A survey using a Discrete Choice Experiment (DCE) was conducted with an online general 
population sample using an existing panel. Respondents were asked to choose whether they 
thought the NHS should treat patient group A or B, who differed in terms of four attributes: 
life expectancy without treatment, HRQOL without treatment, survival gain from treatment 
and HRQOL gain from treatment. These attributes were used to derive BOI, QALY gain and 
EOL. The questionnaire had four variants, each with a different life expectancy without the 
condition (5, 20, 40 and 80 years). Each respondent answered questions for one variant and 
made comparisons between groups with the same life expectancy without the condition. 
Choices were analysed using conditional logistic regression with a range of specifications. 
Robustness across the four levels of life expectancies without the condition and to various 
exclusions was examined. Weights were estimated using the marginal rate of substitution. 
 
Results 
In total, 3669 respondents completed the survey. The sample was largely representative of 
the population of England for age and gender, but there were some differences in other 
characteristics. Regression results indicated that respondents preferred to treat patients with 
larger QALY gains, but at a diminishing rate meaning there was no support for TI. 
Respondents preferred to treat patients with a shorter life expectancy (EOL). Results 
suggested some support for BOI but were not robust across alternative model specifications. 
The coefficients varied as life expectancy without the condition varied. Regressions 
estimated excluding respondents who were identified as possibly misunderstanding the DCE 
task (remaining sample of 2247 respondents) had positive, significant and robust coefficients 
for BOI. Using the marginal rate of substitution to estimate weights indicated that 1 unit of 
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BOI is equivalent to 0.04 QALYs gained, and EOL is equivalent to 3.331 QALYs gained 
(assuming that the value of a QALY does not change with size of QALY gain). 
 
Discussion 
This study provides the first attempt to operationalize the concept of BOI by combining the 
conventional notion of severity (in terms of poor health) with survival, using QALY loss 
attributable to the condition. The results indicate general support for maximising QALY 
gains, but at a diminishing rate, meaning that the evidence did not support the idea of TI. 
The results indicate some support for BOI as a consideration when weighting QALYs. There 
is robust and consistent support for EOL in general (but this conceptually overlaps with BOI 
and the two should not be used together). Overall the results indicate that a QALY is not a 
QALY regardless of the burden of the disease or life expectancy and provide a basis for 
determining appropriate QALY weights. 
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INTRODUCTION 
Economic evaluation is used to inform decisions related to setting priorities in health care 
and whether health care interventions should be reimbursed. A widely used method is to 
enumerate the cost-effectiveness of an intervention in terms of the incremental cost per 
Quality Adjusted Life Year (QALY) and compare this to some threshold cost per QALY to 
reflect displaced activities. (1) The approach is designed to improve the efficiency of health 
care spending and typically assumes that an additional QALY is worth the same regardless 
of who gets it. However, agencies that use cost per QALY analyses allow for other 
considerations explicitly or have been shown to do so implicitly in their decision making. (2)It 
has long been recognised that the QALY approach can incorporate a more complex 
algorithm than simply assuming ‘a QALY is a QALY’. (3) At the same time there is emerging 
evidence that members of the public weight some QALY gains more highly than others 
depending on who receives them. (4-7) 
The literature has uncovered a broad range of attributes across which the value of QALYs 
may be expected to vary including age, health state before treatment, the size of the health 
benefit, socio-economic background of a typical patient, degree of responsibility, and 
broader notions of fair innings. For an attribute to be used in cost per weighted QALY 
analysis it needs both to be supported by normative argument and for empirical evidence to 
quantify its size. The empirical evidence can be elicited in surveys of the general public on 
the grounds that they are potential tax payers or the basis of democratic principles. Most 
research has been undertaken with members of the general public and this suggests that the 
general public does not always favour the view that all additional QALYs are of equal value. 
There is evidence for a preference for those in worse health, though this is not found in all 
studies.(7) There is also evidence that tends to favour younger recipients and those who are 
not responsible for their condition.(8) The legal basis for some of these attributes can be 
challenged, so for example the use of age may be regarded as discriminatory (as would be 
the case in the UK) and responsibility can be hard to establish for most medical conditions. 
Therefore the main idea to emerge from the literature is that those in worse health should be 
given greater priority than those in better health, often referred to as the severity argument.  
An important consideration is the way severity is defined and measured. The earlier 
literature tended to focus on severity in terms of the health related quality of life of the 
recipient before treatment (4;9) finding that respondents often gave gains at the lower end of 
the 1-0 full health-dead scale a higher weight than gains at the higher end of the scale. 
However, this is quite a narrow notion of the severity of a condition or more generally of 
someone’s health profile. The severity of a condition is typically seen in terms of mortality as 
well as the quality of their state of health. As argued by Hansson and colleagues, (10)  
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“Severity of disease can be defined as prognosis without treatment, i.e. expected remaining 
life years adjusted for the quality of life for these years’’. They went on to argue “This implies 
that the same metric (such as Quality Adjusted Life Years or QALYs) can be used for 
comparisons of outcomes with and without treatment. If health benefit with treatment is 
measured along the axes of mortality, pain, physical, mental and social functions, so should 
severity of disease.” (10)(Hansson et al 1994, p353). It has been argued further that equity 
considerations would take into account a person’s whole health profile and not simply that 
from today. This is the basis of a fair innings criterion, whereby the weight of a QALY gain for 
a given recipient depends on what has gone before and what will happen without treatment 
compared to some expectation or target level of survival and health state over time.(11) 
However, decisions are made for the future and it could be argued that prospective health 
should be the focus for decision making.(4) 
The research reported in this paper attempts to operationalize the notion of severity of 
disease set out by Hansson and colleagues (1994) using a metric that is compatible with the 
cost per QALY analysis used by National Institute of Health and Care Excellence (NICE) .(1) 
In a consultation document, the English Department of Health set out a new mechanism for 
pricing drugs in the UK known as Value Based Pricing.(12) Value-Based Pricing aims to 
assess the cost-effectiveness of medicines taking into account a broader scope of value, 
including the severity of disease and wider societal benefits. The consultation specifies 
severity in the same way as Hansson and Colleagues (1994) and refers to this as burden of 
illness (BOI). BOI is measured using the outstanding QALY loss suffered by patients with 
current treatments relative to their prospects in the absence of the disease.  
The consultation document proposes another criterion based on the size of therapeutic 
improvement (TI) to reflect the benefits of those innovations that bring about a ‘step change’ 
in outcome for patients. This attribute has been examined in the literature in terms of 
whether a given benefit of health should be concentrated for the benefit of a few or 
dispersed more widely to the ‘many’. The evidence on this attribute is mixed, with 
respondents often favouring greater dispersion,(13) but there is some evidence to suggest 
that there may be a threshold below which respondents prefer to concentrate QALY gains. 
One study found that respondents tended to prefer to concentrate life year gains below a 
threshold of 9 years (14) and another study found that there was a threshold at 2.6 years. (8) 
The precise threshold is likely to depend on the context, but the existing evidence provides 
some support for concentration, and thus TI, but in a restricted range. 
In addition, this work was being undertaken in the UK policy environment where there 
already exists another attribute that is used in HTA appraisal to weight QALYs. This is the 
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‘end of life’ (EOL) criterion used by NICE which stipulates that a greater weight can be given 
to QALY gains where the recipients have a life expectancy of less than 2 years and a 
survival gain of 3 months or more (provided the condition is a ‘rare’ disease).(15) This 
attribute has also been included in this research. 
The aim of the research presented in this paper was to elicit societal preferences for the 
following attributes: 1) BOI from a medical condition given current health care interventions – 
defined as the QALY loss per patient from a condition due to premature mortality and/or 
reduced health-related quality of life measured against life expectancy and health-related 
quality of life without the condition; 2) TI - whether preferences for large QALY gains are 
disproportionately larger than the size of the gain (e.g. weight a QALY gain of 2 more than 4 
times a QALY gain of 0.5) and 3) EOL - defined by NICE as expected survival of less than 2 
years and expected survival gain of 3 months or more. This paper presents the methods 
developed for operationalizing these attributes, the survey to elicit the preferences of the 
general public using a discrete choice experiment, regression analyses of the survey data 
and QALY weights. The results are detailed together with a discussion of their implications 
for research in this field and health care policy.  
 
Methods 
The framework 
The components of the attributes of BOI, TI and EOL are shown in Figure 1. These 
components are measured from the point at which the treatment decision is being 
considered, such as patients with rheumatoid arthritis who have not responded to first line 
treatment and are being considered for second line treatment. At that point they have a 
health profile without treatment, which for simplicity is represented by health-related quality 
of life or health H and life expectancy E. To estimate the BOI in terms of the QALY loss 
associated with the condition it is necessary to establish an expected or target level of health 
and life expectancy. In this study the expected profile without the condition is assumed to be 
100% health with life expectancy N. The improvement from treatment is represented by a 
gain in health Q and an improvement in survival S. BOI is the loss of health and life 
expectancy from their expected or target levels, measured as QALY loss from morbidity 
(areas B+D in Figure 1), and QALY loss from premature mortality (areas A+C in Figure 1),  
generated as 100*N - area F. QALY gain is areas D+C, and end of life is where E is 2 years 
or less and S is 3 months or more. A diagram like this was used to present the different 
combinations of attributes to respondents in the survey. 
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Elicitation technique 
A DCE based on pairwise comparisons was chosen as the method to elicit preferences. It 
permits the simultaneous consideration of different attributes in a format that is amenable to 
being administered online and has been successfully employed by Lancsar and colleagues 
in a survey eliciting QALY weights.(16) Several preparatory studies were undertaken to 
determine the choice of DCE, the online mode of administration and question framing. These 
included: a review on the social value of a QALY; a large preparatory online survey to pilot 
DCE and person trade-off questions designed to elicit preferences for BOI, QALY gain and 
EOL; a qualitative survey to further explain the findings of the large preparatory online 
survey; and a six-arm online and face-to-face survey examining different framings of 
questions and mode of administration to determine which was most appropriate for eliciting 
preferences for BOI, QALY gain and EOL. For further details see Brazier et al (2014).(17) 
 
Selection of attributes and levels 
The valuation survey consisted of a pairwise comparison DCE with 4 attributes: life 
expectancy without treatment (E), survival gain from treatment (S), health before treatment 
(H), health gain from treatment (Q) (Figure 1). There were 4 different DCE designs, each 
with a different level of life expectancy without the condition (N): 5 years, 20 years, 40 years 
or 80 years resulting in 4 variants of the questionnaire. Respondents saw one questionnaire 
variant i.e. one level of life expectancy without the condition across all DCE pairs that they 
attempted. This was due to concerns that different levels of life expectancies without the 
condition would be confusing for respondents and would highlight the differences in age of 
the two profiles, where age is a consideration that is not politically desirable and is therefore 
not a consideration in the framework. The levels of each of the attributes for each level of life 
expectancy without the condition are outlined in Table 1. These were selected to cover a full 
range of potential levels, including patient groups involving children, but also to ensure 
precision over the more common characteristics of interventions in the UK where patients 
have a small number of years of life expectancy remaining without the condition, with small 
QALY gains. 
 
DCE design 
A full factorial design using the attributes and levels specified in Table 1 would result in a 
very large number of possible profiles, meaning it is infeasible to conduct a valuation survey 
involving every possible profile. Profiles were selected using a D-optimality algorithm (18;19) 
and the true model specified in such a way as to allow for the estimation of an additive 
model including all parameters of interest (using derived variables for QALY gain, BOI and 
EOL rather than the attributes H, Q, E and S in the design). Each experiment was designed 
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to minimise the amount of correlation between the derived variables. Impossible profiles 
(such as profiles involving health after treatment of more than 100%) were excluded from the 
candidate set for the design. In total the DCE designs constituted 580 pairs of profiles, with 
the number of pairs varying across designs depending on the number of attributes and levels 
in the design. Pairs were allocated into 58 combinations (also known as ‘card blocs’) of 10 
pairs. Each combination contained pairs for one level of life expectancy without the 
condition. 
 
Summary statistics of the attribute combinations generated by the DCE design are reported 
in Table 2 for each level of life expectancy. These show the large range in variables 
considered in this survey with QALY gains from 0.005 up to 63, BOI from 1 to 80 QALYs 
lost, and life expectancy from 0.25 to 60 years.  
 
Analysis of data 
The DCE data was modelled based on a random utility theory (RUT) framework. Within the 
RUT framework, utility 𝑈𝑈𝑖𝑖𝑖𝑖 for an individual i was assumed to be a function of an explainable 
utility component 𝑉𝑉𝑖𝑖𝑖𝑖 and a random component 𝜀𝜀𝑖𝑖𝑖𝑖: 
 
     𝑈𝑈𝑖𝑖𝑖𝑖 = 𝑉𝑉𝑖𝑖𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖       (1) 
 
Where j represents the alternatives individuals had within a choice set. The alternative 
chosen by the individual was assumed to confer greater utility than any other alternative. 
Choices were based on a set of attributes captured in 𝑉𝑉𝑖𝑖𝑖𝑖  and other influencing factors that 
were not observed were captured by the random component. DCE data provide the 
alternatives that individuals chose, in this case whether respondents thought the NHS should 
treat patient group A or patient group B. These were modelled using the conditional logistic 
model which models the probability that individual i chose profile j = A, B, for example, so the 
probability of an individual choosing to treat patient group A over B was given by: 
 
𝑃𝑃𝐴𝐴 = exp(𝑉𝑉𝐴𝐴)exp(𝑉𝑉𝐴𝐴)+exp(𝑉𝑉𝐵𝐵)         (2) 
 
where VA and VB represent the utility that the person derived from choosing to treat patient 
group A and B, respectively. There were multiple observations for each individual and the 
estimated models cluster the standard errors at the respondent level to allow for respondent 
effects.  
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V was modelled as a function of attributes z: 
     
         𝑉𝑉 = 𝑓𝑓 (𝑧𝑧)      (3) 
Where z represents:    
• BOI representing burden of illness from both premature death (BOISU, A+C in Figure 1) 
and health loss (BOIQL, B+D in Figure 1) generated using 𝑁𝑁 − 𝐻𝐻
100
𝐸𝐸,  
• QALY representing QALY gain from survival (C in Figure 1) and QALY gain from 
improved health (D in Figure 1) generated using 𝑆𝑆 �𝐻𝐻+𝑄𝑄
100
�+ 𝑄𝑄
100
𝐸𝐸, and  
• a dummy variable to represent EOL using the NICE definition of 2 years life expectancy 
or less (E≤2 years) and survival gain of 3 months or more (S≥3 months)  
BOI and EOL were not included in the same model specification due to conceptual overlap 
in these variables: as EOL profiles have life expectancy of 2 years or less these will also 
have a large BOI. Models were estimated that split BOI into the components of BOI from 
premature death (BOISU) and health loss (BOIQL) to determine whether these components 
differ in their impact on utility. 
 
 
Model specification 
The survey was designed to estimate an additive model where each attribute was entered as 
an independent main effect: 
 
𝑉𝑉 = 𝛽𝛽𝑖𝑖𝑖𝑖𝐳𝐳𝑖𝑖𝑖𝑖  + 𝛾𝛾𝑖𝑖𝑖𝑖𝐰𝐰𝑖𝑖𝑖𝑖   + 𝜀𝜀        (4) 
 
where V represents utility, z represents a vector containing the variables described in the 
section above and w represents the squared terms of each. This additive model specification 
was chosen to keep the model as simple and transparent as possible.  
 
The simple model for QALY gain and BOI is: 
 
𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵 = 𝛽𝛽1𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄+𝛽𝛽2𝐵𝐵𝐵𝐵𝐵𝐵 + 𝜀𝜀     (5) 
 
A more complex regression model including a QALY gain squared term to account for TI is: 
 
𝑉𝑉(2)𝐵𝐵𝐵𝐵𝐵𝐵 = 𝛽𝛽1𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄+𝛽𝛽2𝐵𝐵𝐵𝐵𝐵𝐵+𝛽𝛽3𝑄𝑄𝑄𝑄𝑄𝑄𝑄𝑄2 + 𝜀𝜀    (6) 
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where a positive value for 𝛽𝛽3 indicates an increasing marginal utility as QALY gains increase. 
Plots indicated that a QALY cubed term was not appropriate for the distribution of the data. 
 
Different model specifications are reported representing models examining: BOI and QALY 
gain; BOI (model 𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵), QALY gain and TI (model 𝑉𝑉(2)𝐵𝐵𝐵𝐵𝐵𝐵); BOI split into survival and health, 
QALY gain and TI (model 𝑉𝑉(4)𝐵𝐵𝐵𝐵𝐵𝐵); EOL and QALY gain (model 𝑉𝑉(1)𝐸𝐸𝐵𝐵𝐸𝐸); and EOL, QALY gain 
and TI (model 𝑉𝑉(2)𝐸𝐸𝐵𝐵𝐸𝐸). 
 
Model performance 
Performance of all regression models was assessed using the log-likelihood, Rho-squared, 
Akaike Information Criterion (AIC) (20) and the Schwarz Bayesian Information Criterion 
(BIC). (21) Models were preferred with higher log likelihood, larger Rho-squared and lower 
AIC and BIC.  
Robustness of results 
Robustness of results was assessed for the impact of excluding responses from individuals 
who may have not understood or engaged with the survey. A number of exclusion criteria 
were examined to identify these individuals including: those who reported that they found the 
survey quite or very difficult, those who took less than 5 minutes or more than 60 minutes to 
complete the survey and those who selected to treat the same patient group for all 10 
questions (this may indicate respondents were selecting either all left or all right sides of the 
screen). In addition respondents were excluded if they were identified as having possibly 
misunderstood the DCE task. These were respondents who chose to treat the patient group 
with a larger number of total lifetime QALYs after treatment, but smaller QALY gain from 
treatment and lower BOI before treatment than the other patient group. These respondents 
were excluded on the grounds that they seemed to choose the profile they thought was best 
for them personally or that they wanted to live in, not the profile which was best from a 
societal perspective where the patients were most “deserving” of treatment.  
A final check was done by separately excluding the first and last survey questions that 
respondents completed on the basis that these responses may be less reliable. Questions 
were allocated to respondents in a random order and therefore exclusion of the first or last 
question should have no systematic impact on results.  
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 Estimating weights 
The marginal rate of substitution (MRS) was used to indicate the value for BOI in terms of 
QALY gain. The MRS was estimated using the ratio of the marginal utilities:  
 
𝑀𝑀𝑀𝑀𝑆𝑆𝐵𝐵𝐵𝐵𝐵𝐵 = −𝑀𝑀𝑈𝑈𝐵𝐵𝐵𝐵𝐵𝐵 𝑀𝑀𝑈𝑈𝑄𝑄𝐴𝐴𝐸𝐸𝑄𝑄⁄ = − 𝜕𝜕𝜕𝜕𝜕𝜕𝐵𝐵𝐵𝐵𝐵𝐵 𝜕𝜕𝜕𝜕𝜕𝜕𝑄𝑄𝐴𝐴𝐸𝐸𝑄𝑄�     (7) 
 
Where 𝑀𝑀𝑈𝑈𝐵𝐵𝐵𝐵𝐵𝐵 represents the marginal utility of BOI and 𝑀𝑀𝑈𝑈𝑄𝑄𝐴𝐴𝐸𝐸𝑄𝑄 represents the marginal 
utility of the QALY gain, generated using the first order partial derivative of the utility function 
with respect to BOI and QALY gain respectively. For the model specified in equation (5) this 
is: 
𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐵𝐵𝐵𝐵𝐵𝐵 = −𝛽𝛽�2𝛽𝛽�1     (8) 
 
For the model specified in equation (6) this becomes: 
 
𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐵𝐵𝐵𝐵𝐵𝐵 = − 𝛽𝛽�2𝛽𝛽�1+2𝛽𝛽�3𝑄𝑄𝐴𝐴𝐸𝐸𝑄𝑄      (9) 
 
MRS for EOL, 𝑀𝑀𝑀𝑀𝑆𝑆𝐸𝐸𝐵𝐵𝐸𝐸, is generated using equivalent regression specifications involving 
EOL rather than BOI. The regressions selected to generate the coefficients were estimated 
using all data collected in the survey, and used observations across all variants of the 
questionnaire (5, 20, 40 and 80 years of life expectancy without the condition). The rationale 
for using all data was to obtain a representation of the data across all levels of life 
expectancy without the condition. The standard error (S.E.) and the 95% confidence interval 
(95% CI) of the MRS were calculated using the Delta method (see e.g. Hole, 2007).(22) 
 
The survey 
Respondents from an online panel were contacted via email to participate in the survey. 
Respondents were sampled to be representative of the UK adult population in terms of age 
(minimum age 18) and gender. At the start of the survey respondents read an information 
page and gave informed consent to participate in the survey. Respondents were then shown 
a short video explaining the questions. It could not be guaranteed that respondents watched 
the video, but the video had to be played in full before the respondent could proceed to the 
practice questions.  
 
13 
 
The survey had 2 practice questions which involved a “feedback screen” including an 
explanation of their choice with a chance for respondents to change their mind. The first 
question had one “dominant” alternative, which had a larger QALY gain than the other 
alternative, while all other attributes were the same. The second question also had one 
dominant alternative, which had a larger BOI, while all other attributes were the same. Figure 
2 shows the information displayed on the first screen of practice question 1 with a life 
expectancy without the condition of 20 years. Figure 3 shows the feedback screen for a 
respondent who chose to treat Patient group A. Respondents were asked on the feedback 
screen whether they still wished to treat that Patient group.  They started the next question if 
they did not change their mind, and were shown the question from the first screen again if 
they did change their mind. Respondents were allowed up to 7 attempts at each practice 
question before moving on automatically to the next question. 
 
After the 2 practice questions respondents completed 10 DCE questions, 9 questions on 
attitudes, and 17 questions covering EQ-5D of their own health, socio-demographics, 
difficulty of understanding of the DCE and attitudinal questions, and what they thought of the 
survey. The ordering of the 10 DCE questions was random for each respondent. Attitude 
questions were included to determine respondents’ general views on BOI, TI and EOL. This 
enables interpretation of the results of the practice questions, regression modelling and 
weightings, as these should be in accordance with the results of the attitude questions that 
remove the complexities and intricacies of the DCE questions. The framing of the DCE 
questions, the attitude questions and the socio-demographic and understanding questions 
were all piloted in the preparatory studies undertaken prior to this survey. 
 
The Data 
A total of 3669 respondents completed the online survey, providing a response rate of 55% 
of people who accessed the survey. All respondents completed every question. No 
respondents were excluded from the main analysis. Characteristics of the sample were 
compared to the general population in England in Table 3. In comparison to the general 
population of England, the sample was largely representative for age and gender, but had 
higher proportions of individuals who were unemployed, long-term sick and retired, and 
lower proportions of individuals who were employed or self-employed. The sample also had 
a lower EQ-5D score (23) than the general population of England, indicating poorer health. 
Although 66.9% of individuals stated their health in general was good or very good, 37% 
stated that they were limited by a long-term health condition or disability and 33.6% stated 
they had experienced a serious illness in themselves. A large proportion of the sample, 
48.2%, had a degree or equivalent professional qualification. 
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 RESULTS 
Completion times 
Median completion time from consent to the end of the survey was 21 minutes (IQR 17-27 
minutes) with the majority of respondents (≈ 80%) spending less than 30 minutes on the 
survey but a small proportion (≈ 5%) of respondents took over an hour. A large proportion of 
respondents (65%) spent between 7 and 10 minutes on watching the introduction video and 
completing the practice questions, suggesting the respondent watched the video (which 
lasted approximately 5 minutes 50 seconds) and then considered the practice questions. 
However, some respondents had long times (up to 1 hour) that suggested they may have left 
the survey idle in this time and therefore there are doubts as to whether these respondents 
watched the video. 
 
Practice questions 
In practice question 1, respondents overwhelmingly (93.0%) chose to treat the group with 
the highest QALY gain, all other things the same, and this was consistent across the 
different variants, varying from 90.7% to 92.5% (see Table 4). In practice question 2 there 
was little evidence (50.8%) that, other things equal, respondents preferred to treat the 
patient group with higher BOI, with 46.8%, 54.3%, 52.3% and 50.7% of respondents across 
the four questionnaire variants choosing this group. Following the feedback on their choice, 
where respondents were offered the option to change their mind up to 7 times in each 
practice question, the final responses differed to their first response for 2-4% of respondents. 
These results suggest that the feedback did clarify the profiles for some respondents and 
that a small number of respondents altered their choices following the feedback. In 
robustness analyses, excluding respondents identified as possibly misunderstanding the 
DCE task increased the proportion choosing to treat the patient group with higher BOI to 
63.5% (remaining n=2247). 
 
Regression results 
Table 5 presents the main regression results. The coefficients varied across the different 
variants meaning that the coefficients vary as life expectancy without the condition varies. 
 
Across all models, QALY gain had a positive and significant coefficient, indicating that 
respondents preferred profiles with higher QALY gains.  The coefficient for the QALY gain 
squared term, when included, was negative and significant across all variants and models, 
indicating that QALY gains were preferred at a decreasing rate.  This means that there was 
no support for TI; in fact the opposite was observed. 
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 The coefficient for BOI, when included, was small, positive and significant for the pooled 
analysis, indicating that respondents preferred profiles with higher BOI.  However, results by 
life expectancy variant varied, where BOI was non-significant for the 20 year variant in 
models 𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵 and 𝑉𝑉(2)𝐵𝐵𝐵𝐵𝐵𝐵; and for the 80 year variant in model 𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵. BOI squared was tested 
but did not improve the models and although it was statistically significant in some models, 
the BOI main effects term was no longer statistically significant hence the squared term has 
not been included here. In models where BOI was split into health loss and life expectancy 
loss, coefficients were not always significant across variants, but when they were, BOI from 
health loss (BOIQL) was negative while burden from life expectancy loss (BOISU) was 
positive. This indicates that respondents were more likely to choose to treat patient groups 
with higher burden from life expectancy and lower burden in health. These coefficients were 
not consistent in direction between the questionnaire variants, but the coefficients were not 
statistically significant where the direction was inconsistent.  
 
The coefficient for EOL was positive and significant indicating respondents gave greater 
weight to shorter life expectancy before treatment when survival gains were greater than 3 
months. 
 
Comparison of model performance 
Model performance was improved by the inclusion of the QALY squared term. The best 
performing models using AIC, BIC, log likelihood and Rho-squared were the specifications 
with either EOL or BOI split into health and life expectancy losses. 
  
Robustness of results 
The robustness of results was examined as there were concerns that respondents who did 
not understand or engage with the survey may have had an impact on results. First, the 
consequences were examined of excluding each of the following: 279 individuals who 
reported they had difficulty understanding the DCE questions; 208 individuals who took less 
than 5 minutes or more than 60 minutes to complete the survey; 23 individuals who chose 
the same option for all their DCE questions; all responses to the first DCE non-practice 
questions; and all responses to the last DCE non-practice questions. The exclusions 
impacted on the magnitude of the coefficients but not their sign or significance with the 
exception of BOI. Excluding individuals who took less than 5 minutes or more than 60 
minutes to complete the survey changed the significance for BOI when life expectancy 
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without the condition was 80 years. This means that, contrary to expectations, the BOI 
coefficient was negative and significant in model 𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵 when life expectancy without the 
condition was 80 years. Excluding the first question for each individual meant that the BOI 
coefficient became insignificant in model 𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵 when life expectancy without the condition 
was 5 years. Excluding the last question for every individual meant that the BOIQL 
coefficient became insignificant in model 𝑉𝑉(3)𝐵𝐵𝐵𝐵𝐵𝐵 when life expectancy without the condition 
was 40 years.  
 
Second, 1422 respondents who were identified as possibly having misunderstood the DCE 
task were excluded. For questionnaire variants with 5, 40 and 80 years life expectancy 
without the condition, some respondents did not answer a question that could be used to 
implement this exclusion criterion. These 369 respondents remain in the analysis although it 
is possible that some of these respondents may have also misunderstood the DCE task. In 
regressions estimated on the remaining sample (n=2247) there was no impact on the 
coefficients for QALY gain, QALY gain squared and EOL in terms of significance and 
direction although there were some changes in magnitude. However, the coefficient for BOI 
was larger, positive and significant for all models. When BOI was split between losses in life 
expectancy and health the coefficients were always positive and were significant with the 
exception of the 80 year variant for BOI from health loss (BOIQL). 
 
Weights  
The 𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐵𝐵𝐵𝐵𝐵𝐵 of 1 unit loss of BOI is -0.040 QALYs (95% CI (-0.068, -0.013)). In other words, 
this indicates that if BOI increases by 1 unit, the level of utility is maintained by a QALY loss 
of 0.040 QALYs. This calculation assumes that the social value of a QALY gain does not 
change with size of QALY gain. If the QALY gain squared term is included in the model the 
𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐵𝐵𝐵𝐵𝐵𝐵 is -0.064 QALYs when the QALY gain is 1 (95% CI (-0.082, -0.047)). However, the 
weighting for one extra unit of BOI now differs depending on the size of QALY gain as shown 
in Table 6, ranging from -0.063 to -0.141 as QALY gain changes from 0.05 to 20.  
 
The 𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐸𝐸𝐵𝐵𝐸𝐸 of moving from not being EOL to being EOL is -3.331 QALYs (95% CI (-3.711, -
2.950)). In other words, this indicates that by moving from not being EOL to being EOL, the 
level of utility is maintained by a QALY loss of 3.331. If the QALY gain squared term is 
included in the model the 𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐸𝐸𝐵𝐵𝐸𝐸 is -2.229 QALYs for a QALY gain of 1 (95% CI (-2.438, -
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2.020)). Allowing the value of a QALY gain to vary by the size of the QALY gain results in a 
range in 𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐸𝐸𝐵𝐵𝐸𝐸 of -2.170 to -4.875 as QALY gain changes from 0.05 to 20. 
 
Attitudinal questions  
The results suggest some support for BOI, with between 40.7% and 53.9% of respondents 
agreeing that the NHS should give priority to treating patients with BOI over giving the same 
priority to treating all patients regardless of how ill they are or when they will die. However, 
only 9.5% of respondents agreed that the NHS should give priority to treating patients with 
BOI if the patients only get a small amount of benefit from treatment.  
 
There was some support for EOL, with between 44.7% and 60.3% of respondents agreeing 
that the NHS should give priority to patients who are expected to die soon over giving the 
same priority to treating all patients regardless of how ill they are or when they will die. 
However, only 13.1% of respondents agreed that the NHS should give priority to patients 
who are expected to die soon if they were at the natural end of their life, and only 3.9% 
agreed with giving priority to these patients if they live in very poor health. Furthermore only 
12.0% of respondents agreed that the NHS should give priority to extending the life of 
patients expected to die soon over giving the same priority to all patients.  
 
There was very little support for TI and concentrating gains, with only 8.1% of respondents 
agreeing that the NHS should give priority to treatments giving a large amount of benefit to a 
small number of patients.  
 
Overall the responses to the attitudinal questions indicated that most respondents believed 
that the NHS should give preference to the group with the largest treatment gain over BOI or 
EOL (see Table 7). A large proportion of respondents consistently indicated that the same 
priority should be given to all patients implying that they did not want size of QALY gain, BOI 
or EOL to be taken into account, and this was the modal response.  
 
Respondent views of the survey 
The majority of respondents, 77.7%, reported that the DCE questions were either very easy 
or fairly easy to understand, varying from 76.2% to 79.5% across the different life 
expectancies without the condition. The majority of respondents, 77.7% also reported that 
the attitudinal questions were either very easy or fairly easy to understand, varying from 
76.2% to 80% across the life expectancies without the condition. 
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DISCUSSION 
Summary 
This was the first study to examine societal preferences for BOI alongside TI and EOL. It 
was a large DCE survey using an existing online panel drawn from the general population. 
Respondents preferred to treat patients who had larger QALY gains but this was at a 
diminishing rate. They also preferred to treat patients at the EOL using the NICE definition. 
The results for BOI were less robust across variants of the questionnaire, but suggested 
some modest support for BOI. Using the MRS to estimate weights indicated that 1 unit of 
BOI is equivalent to 0.04 QALYs gained, and EOL is equivalent to 3.331 QALYs gained. 
Attitudinal questions seemed to support the regression results for QALY gains and BOI 
although less so for EOL. 
 
QALY gains and therapeutic improvement 
The results of this survey indicate that respondents tend to choose to treat the group with the 
larger QALY gain, but they do not support the notion of TI set out in the VBP consultation 
document.(12) Although not directly comparable in terms of the attributes included, the 
Lancsar et al (2011) study undertaken in the UK found QALY gains to have a positive and 
statistically significant impact but again at a declining rate, and so did a recent study in 
Australia by Norman et al (2013). This is also consistent with studies finding evidence for 
dispersing life year gains above a threshold,(8;14) although the current survey was not 
designed to examine this. 
 
EOL  
The regression results showed support for EOL across the regression models, with evidence 
for a preference to treat those who were at the end of their life.  However, the responses to 
the attitudinal questions cast some doubt on the strength of this finding as this was not a 
view held by the majority. The evidence of a preference for EOL is consistent with a small 
survey conducted by Shah et al (2013) which found weak support for EOL.  Conversely, their 
larger follow-on study indicated little support for EOL,(24) and a survey by Linley and 
Hughes (2013) also found no support for EOL. Whilst these contradictory results are 
surprising, this may in part be due to differences in framing across the surveys. 
 
BOI 
The findings from the attitude survey and the DCE suggest some support for BOI, though the 
findings are not consistent across all models. Whilst the responses to practice question 2 
found little support for BOI with 50.8% of respondents choosing the option with higher BOI, 
there were other questions in the survey with dominant pairs or near dominant pairs in terms 
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of BOI (34 pairs) that provided more support. Analyses of these revealed a majority of 
respondents typically choosing the group with the higher BOI at 52-85%. 
 
Splitting the BOI term indicated different effects of burden from health loss (BOIQL) and 
burden from shorter life expectancy (BOISU). The surprising negative coefficients on BOIQL 
were probably observed because BOIQL was not solely attributable to health loss (in terms 
of Figure 1, it is the product of without treatment health H and life expectancy E). BOIQL can 
increase due to either a reduction in H or an increase in E, and these are likely to impact 
differently on how the without treatment profile is regarded. Therefore BOIQL cannot be 
seen as a test of the conventional severity argument and BOI should not be split into a 
health effect and a survival effect, since by definition BOI is composed of both. However, 
some recent large scale studies with members of the general population, including Lancsar 
et al (2011) and Norman et al (2013), found that respondents were less likely to choose to 
treat patients with a lower quality of life before treatment, H, which is consistent with our 
findings. 
 
BOI provides a broader notion of severity than previous research since it incorporates the 
impact on health and life expectancy over the patients’ future life. Furthermore the survey 
incorporates end of life. On theoretical grounds BOI and EOL should not be used together 
either in regressions or to weight QALY gains as profiles with EOL will also have a large 
BOI. There is an important policy decision about which measure to include. The advantage 
of BOI is that it incorporates a number of different equity concerns. A further attraction of the 
way BOI has been operationalized is that it is measured using QALYs and so is compatible 
with cost-effectiveness in terms of cost per QALY gain.  
 
Weights 
The weights for BOI are much smaller than the weights for EOL, but this is expected due to 
the differences in the definitions of these concepts as EOL is either present or not whereas 
the size of BOI varies and the weighting for BOI is for each unit of BOI. It is recommended 
that the weights generated using regressions without a QALY squared term 
(𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐵𝐵𝐵𝐵𝐵𝐵 ,𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐸𝐸𝐵𝐵𝐸𝐸) are preferable for use in policy, as these assume that the value of a QALY 
gain is equal regardless of the number of QALYs gained. The weights derived using 
regressions including a QALY squared term (𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐵𝐵𝐵𝐵𝐵𝐵,𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐸𝐸𝐵𝐵𝐸𝐸) allow that the societal value 
of a QALY gain changes as the number of QALYs gained changes. This means that these 
weights reflect a societal preference that values larger QALY gains proportionately lower, 
and hence are not only a reflection of the societal weighting for BOI or EOL. However for 
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both 𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐵𝐵𝐵𝐵𝐵𝐵 and 𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐵𝐵𝐵𝐵𝐵𝐵 the proportional weight given to each unit of BOI reduces as the 
size of QALY gain from treatment increases. For example for 𝑀𝑀𝑀𝑀𝑆𝑆(1)𝐵𝐵𝐵𝐵𝐵𝐵 the weight for 10 units 
of BOI is 0.4 (10*0.040) regardless of whether QALY gain is 0.05, 0.5 or 5, but 
proportionately the weight for BOI differs relative to the size of the QALY gain. This means 
that BOI is proportionately less important when the QALY gain is large. This occurs as a 
result of the additive models used to model the data and is a potential limitation of this 
approach. 
 
Limitations 
An important concern with this survey is the use of an online sample and whether it is 
representative of the nation. An online sample may exclude groups in society such as the 
computer illiterate or those unable to access a computer. The use of an online panel means 
that respondents have stated that they are willing to regularly answer online surveys, and 
this also makes them unrepresentative of computer users. Respondents receive points for 
every survey they complete that can be exchanged for goods, which also may lead to the 
motivation for answering the survey to be questioned. The importance of these selection 
processes for the answers obtained in the survey is not known. However, the recruitment 
used a nationally representative quota for age and gender, and for these characteristics the 
sample is nationally representative. 
 
Preparatory studies undertaken before the main survey suggested that some respondents 
failed to understand the concept of BOI in the DCE task. This main survey was therefore 
designed to minimise this problem and comprised: an introduction video, practice questions 
involving a feedback screen and profiles that included pictures to aid understanding.  
Respondents’ views of the survey indicated that the majority of respondents did not find 
either the DCE tasks or the attitudinal questions difficult, suggesting that respondents felt 
that they understood the questions that were asked. Robustness analyses excluding the first 
question for each individual had an impact on BOI coefficients in terms of significance or 
direction in only 2 of all 35 models, suggesting there were no significant learning effects in 
the study. However, excluding respondents who may not have understood or engaged with 
the survey did impact on the direction and significance of the coefficients for BOI (with only 
changes in magnitude for all other coefficients). Over one third (38.8%) of respondents 
chose to treat a patient group with a larger number of total lifetime QALYs after treatment, 
but smaller QALY gain from treatment and lower BOI before treatment than the other profile, 
suggesting that they may have misunderstood the DCE task. A further 10.1% of respondents 
did not see a question of this type. In robustness analyses the exclusion of the respondents 
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who were identified as possibly misunderstanding the task in this way had an impact on the 
results for BOI, affecting the significance and magnitude of the coefficients, but had little 
impact on the results for QALY gain and EOL. This has an impact on the results for BOI as 
these respondents were choosing to treat the patient group with lower BOI. It is possible that 
some of the respondents identified as possibly misunderstanding the task were expressing a 
genuine societal preference, yet this is unlikely to explain all of these responses. Overall the 
robustness analyses suggest that the coefficients and weights estimated for BOI using all 
data may be an underestimation as some respondents may have misunderstood the DCE 
task regarding BOI. 
 
Overall, the results indicated that life expectancy without the condition in the profiles (N) 
impacted on the size of the coefficients. This indicates that framing may affect results even 
when respondents see a single life expectancy as has been used in other studies that have 
followed a similar approach (e.g. Shah et al (2012)). This also has implications for the pooled 
models that combine the data across all life expectancies without the condition, and for the 
weights that are based on the pooled data.  
 
In the attitude questions a large number of respondents chose to give equal priority to 
treating all patients, yet respondents were not allowed to give equal priority to treating both 
patient groups in the DCE task. This can be seen as a limitation of the DCE task as 
respondents had to choose whether the NHS should treat either patient group A or patient 
group B where the respondent may have been indifferent between treating either group. 
However forced choices for a small group of respondents should create random noise in the 
analysis rather than affect the results. In addition the attitudinal responses may also be 
reflecting a preference regarding equal access to health care when a patient is in need, 
rather than a rejection of BOI, EOL or TI. It must also be remembered that the attitudinal 
questions are dichotomous questions that do not involve trade-offs.  
 
The experimental design of the DCE requires that the regression specifications are additive. 
All weights are therefore based on this assumption, yet the results may be affected by a 
possible interaction between the levels of BOI and QALY gains. The additive model also 
means that weights can be produced for interventions with positive BOI or EOL even when 
the QALY gain is zero. However it is unlikely in a policy context that weights would be 
required for an intervention providing zero QALY gains. 
 
Other possible limitations are the assumption of zero time preference and the exclusion of 
age from the attributes and conceptual framework used in the survey. Furthermore the 
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concepts of EOL and TI are constrained by the definitions used in the survey. The NICE 
definition of end of life states under 2 years life expectancy whereas the models estimated 
here use 2 years or less due to the limited number of levels for the life expectancy variable. 
The NICE definition also requires that the condition is a ‘rare’ disease, but this has not been 
considered here.(15) Therapeutic improvement and innovation as outlined by DH may imply 
a treatment involving technological innovation, but the survey here has focussed solely upon 
the impact of the treatment on the size of QALY gain.(12) 
 
CONCLUSION 
This study provides the first attempt to operationalize the concept of BOI by combining the 
conventional notion of severity (in terms of poor health) with survival, using QALY loss 
attributable to the condition. It also provides evidence on societal preferences for EOL and 
TI. The results indicate general support for maximising QALY gains, with some support for 
BOI as a consideration when weighting QALYs. The evidence did not support the idea of TI. 
There is robust and consistent support for EOL in general, but this conceptually overlaps 
with BOI and the two should not be used together. Overall there seems to be a strong 
preference for larger QALY gain but at a diminishing rate. These results indicate that a 
QALY is not a QALY regardless of the burden of the disease or life expectancy and provides 
a basis for determining the appropriate weights.   
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 Figure 1: Representation of profile used in survey 
 
 
 
 
 
 
 
 
 
 
 
Where N = life expectancy without the condition, E = life expectancy without treatment, S = survival gain from treatment, H = health before 
treatment, Q = health gain from treatment 
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Figure 2 (pictures on next page): Practice Question 1 when normal life expectancy=20, first screen 
 
Both groups of patients have a medical condition, and this affects their health and how long they live 
 
Patient group A 
Without treatment 
• will live for 10 years from today 
• with 50% health 
 
With treatment 
• will live for 11 years from today 
• with 60% health 
 
Patient group B  
Without treatment 
• will live for 10 years from today 
• with 50% health 
 
With treatment 
• will live for 12 years from today 
• with 70% health 
If these patients did not have a medical condition 
they would live in 100% health for 20 years from today 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only 1 patient group can be treated, the other patient group will live for the rest of their life without treatment 
Which patient group do you think the NHS should treat? 
 
Please make sure you consider in your answer: 
• the life of each patient group without treatment 
• the life of each patient group with treatment 
• the life of each patient group if they did not have a medical condition 
 
There are the same number of patients in each patient group. 
 
Remember that you can treat only 1 patient group. 
 
The patient group you do not treat will live the life without treatment. 
 
Patient group A 
              □ 
Patient group B 
              □ 
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Without treatment Treatment gain No condition 
Patient group A Patient group B 
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Figure 3: Practice Question 1 when normal life expectancy=20, feedback screen when respondent chose to treat Patient group A 
Both groups of patients have a medical condition, and this affects their health and how long they live 
 
Patient group A 
Without treatment 
• will live for 10 years from today 
• with 50% health 
 
With treatment 
• will live for 11 years from today 
• with 60% health 
 
Patient group B  
Without treatment 
• will live for 10 years from today 
• with 50% health 
 
With treatment 
• will live for 12 years from today 
• with 70% health 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The impact on how long the patients live and their health from having the medical 
condition was the same for both patient groups. 
 
You chose that the NHS should treat patient group A. 
 
These patients will live for 11 years from today with 60% health.  
 
Patient group B will not be treated. These patients will live for 10 years from today 
with 50% health. 
 
You have chosen the treatment that gives the smallest treatment gain. 
 
Do you still think that the NHS should treat patient group A? 
Yes 
  □ 
 No 
  □ 
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Table 1: Survey attributes and levels 
Attribute Levels Levels Levels Levels 
Life expectancy without the 
condition, N 
 
5 years 20 years 40 years 80 years 
Life expectancy without treatment, E 3 months  
6 months  
9 months 
1 year  
2 years  
5 years 
3 months  
1 year 
2 years  
5 years  
10 years 
3 months  
1 year 
2 years  
5 years  
10 years  
30 years 
3 months 
1 year  
2 years  
5 years 
10 years  
30 years  
60 years 
Survival gain from treatment, S 0 
1 month 
3 months  
6 months 
9 months  
1 year  
3 years 
0  
3 months  
6 months  
1 year 
3 years 
10 years 
0  
3 months  
6 months  
1 year 
3 years 
10 years 
0  
3 months  
6 months  
1 year 
3 years 
10 years 
60 years 
Health without treatment (%), H 10 20 40 60 80 10 20 40 60 80 10 20 40 60 80 10 20 40 60 80 
Health gain from treatment (%), Q 0 2 5 10 20 30 60 0 2 5 10 30 60 0 2 5 10 30 60 0 2 5 10 30 60 
 
Number of pairs 160 120 140 160 
Combinations of pairs (card blocs) 16 12 14 16 
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Table 2: Summary of statistics derived from the DCE design 
 Normal life expectancy 5 20 40 80 
QALY gain Mean (s.d.) 0.673 (0.744) 2.039 (2.638) 3.012 (4.219) 8.510 (13.640) 
 Minimum 0.005 0.0125 0.005 0.005 
 Maximum 3.4 16 21 63 
      
QALY gain due to survival Mean (s.d.) 0.442 (0.642) 1.417 (2.336) 1.462 (2.389) 5.792 (12.722) 
 Minimum 0 0 0 0 
 Maximum 3 10 10 60 
      
QALY gain due to health Mean (s.d.) 0.231 (0.427) 0.623 (1.205) 1.549 (3.490) 2.718 (6.416) 
 Minimum 0 0 0 0 
 Maximum 3 6 18 36 
      
BOI Mean (s.d.) 4.507 (0.651) 18.518 (1.931) 36.487 (5.449) 73.349 (10.899) 
 Minimum 1 12 16 32 
 Maximum 4.975 19.975 39.975 79.975 
      
Life expectancy without treatment Mean (s.d.) 1.206 (1.229) 3.621 (3.585) 8.665 (10.696) 15.599 (20.582) 
 Minimum 0.25 0.25 0.25 0.25 
 Maximum 5 10 30 60 
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Table 3: Sociodemographic characteristics 
 All respondents England* 
N 3669  
Mean age (s.d.) 46.5 (16.6) NA 
Age distribution   
       18-40 39.9% 41.6% 
       41-65 42.1% 39.1% 
       Over 65 18.0% 19.3% 
Female 54.3% 51.3% 
Married/Partner 62.4% NA 
Employed or self-employed 47.3% 60.9% 
Unemployed 6.2% 3.4% 
Long-term sick 6.4% 5.3% 
Full-time student 7.2% 7.3% 
Retired 23.8% 13.5% 
Secondary school is highest level of education 21.6%  
Degree or equivalent professional qualification 48.2%  
Health in general is very good or good 66.9%  
Limited by long term health condition or disability 37.0%  
EQ-5D score, mean (s.d.) 0.78 (0.26) 0.86 (0.23)† 
Experienced serious illness in yourself 33.6%  
Experienced serious illness in family 74.5%  
Experienced serious illness in caring for others 33.5%  
Found DCE questions quite or very difficult to understand 7.6%  
Found attitudinal questions quite or very difficult to understand 6.6%  
Median completion time in minutes from consent to end of survey (Interquartile range) 21 (17-27)  
Notes: * Statistics for England in the Census 2001. Questions used in this study and the census are not identical. The census includes persons aged 16 and above whereas 
this study only surveys persons aged 18 and above. Age distribution is here reported as the percentage of all adults aged 18 and over. 
† Interviews conducted in the Measurement and Valuation of Health (MVH) study (Kind et al, 1999). NA=Not available 
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Table 4: Responses to practice questions 
Practice Question Normal life expectancy Practice question 
First response 
Practice question 
Second response 
Practice question 
Final response 
n A B n A B n A B 
1 5 1022 7.7% 92.3% 42 26.2% 73.8% 1022 6.8% 93.2% 
20 760 8.7% 91.3% 28 14.3% 85.7% 760 7.1% 92.9% 
40 889 9.3% 90.7% 54 22.2% 77.8% 889 7.8% 92.2% 
80 998 7.5% 92.5% 55 23.6% 76.4% 998 6.5% 93.5% 
All respondents 3669 8.3% 91.7% 179 22.3% 77.7% 3669 7.0% 93.0% 
2 
 
 
5 1022 41.9% 58.1% 77 68.8% 31.2% 1022 46.8% 53.2% 
20 760 50.4% 49.6% 45 75.6% 24.4% 760 54.3% 45.7% 
40 889 48.5% 51.5% 60 65.0% 35.0% 889 52.3% 47.7% 
80 998 47.5% 52.5% 70 61.4% 38.6% 998 50.7% 49.3% 
All respondents 3669 46.8% 53.2% 252 67.1% 32.9% 3669 50.8% 49.3% 
Notes: Respondents who stated after the explanation of their choice that they did not still want to treat the same group were asked the question again. 
Respondents were allowed up to 7 attempts at each practice question before moving on automatically to the next question. 
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Table 5: Regression analysis  
   Life expectancy without the condition 
 Variables All variants 5yrs 20yrs 40yrs 80yrs 
𝑉𝑉(1)𝐵𝐵𝐵𝐵𝐵𝐵 QALY 0.149*** 1.813*** 0.437*** 0.191*** 0.086*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 BOI 0.006*** 0.068* -0.015 0.028*** -0.003 
  (0.005) (0.057) (0.328) (0.000) (0.156) 
 Log likelihood -22604 -5466 -4153 -5421 -5615 
 Rho-squared 0.111 0.228 0.212 0.120 0.188 
 AIC 45212 10936 8309 10847 11234 
 BIC 45229 10950 8323 10861 11248 
𝑉𝑉(2)𝐵𝐵𝐵𝐵𝐵𝐵 QALY 0.276*** 3.641*** 0.751*** 0.404*** 0.171*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.004*** -0.709*** -0.037*** -0.014*** -0.002*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 BOI 0.017*** 0.120*** -0.000 0.039*** 0.005* 
  (0.000) (0.001) (0.999) (0.000) (0.068) 
 Log likelihood -21775 -5160 -4043 -5246 -5416 
 Rho-squared 0.144 0.272 0.232 0.149 0.217 
 AIC 43555 10326 8093 10498 10838 
 BIC 43581 10348 8114 10519 10859 
𝑉𝑉(3)𝐵𝐵𝐵𝐵𝐵𝐵 QALY 0.309*** 3.626*** 0.784*** 0.434*** 0.192*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.004*** -0.698*** -0.039*** -0.014*** -0.002*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 BOIQL -0.027*** 0.000 -0.071*** -0.012* -0.020*** 
  (0.000) (0.993) (0.000) (0.072) (0.000) 
 BOISU 0.009*** 0.150*** -0.003 0.033*** -0.000 
  (0.000) (0.000) (0.870) (0.000) (0.994) 
 Log likelihood -21489 -5148 -4013 -5138 -5346 
 Rho-squared 0.155 0.273 0.238 0.166 0.227 
 AIC 42987 10303 8034 10284 10700 
 BIC 43021 10332 8062 10312 10729 
𝑉𝑉(1)𝐸𝐸𝐵𝐵𝐸𝐸 QALY 0.156*** 1.628*** 0.455*** 0.190*** 0.088*** 
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   Life expectancy without the condition 
 Variables All variants 5yrs 20yrs 40yrs 80yrs 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 EOL 0.521*** 0.871*** 0.359*** 0.479*** 0.152*** 
  (0.000) (0.000) (0.000) (0.000) (0.001) 
 Log likelihood -22284 -5312 -4119 -5378 -5610 
 Rho-squared 0.124 0.250 0.218 0.127 0.189 
 AIC 44571 10627 8243 10761 11225 
 BIC 44588 10642 8256 10775 11239 
𝑉𝑉(2)𝐸𝐸𝐵𝐵𝐸𝐸 QALY 0.281*** 3.230*** 0.762*** 0.400*** 0.175*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 QALY_sq -0.004*** -0.602*** -0.037*** -0.014*** -0.002*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 EOL 0.609*** 0.607*** 0.375*** 0.576*** 0.314*** 
  (0.000) (0.000) (0.000) (0.000) (0.000) 
 Log likelihood -21411 -5103 -4008 -5203 -5395 
 Rho-squared 0.158 0.280 0.239 0.156 0.220 
 AIC 42829 10213 8022 10411 10797 
 BIC 42854 10233 8042 10433 10818 
 Observations 73,380 20,440 15,200 17,780 19,960 
Notes: P values in parentheses. * significant at 10%, ** significant at 5%; *** significant at 1%. 
QALY – quality adjusted life year gains; BOI – burden of illness measured as QALY loss; BOIQL – QALY loss due to poor HRQOL; BOISU – QALY loss due to shorter life expectancy; EOL – life 
expectancy before treatment ≤2 years and survival gain≥ 3 months. 
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Table 6: Marginal rate of substitution for BOI and EOL by size of QALY gain (𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐵𝐵𝐵𝐵𝐵𝐵, 𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐸𝐸𝐵𝐵𝐸𝐸) 
QALY gain 0.05 0.1 0.5 1 2 5 10 20 
𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐵𝐵𝐵𝐵𝐵𝐵* -0.063 -0.063 -0.063 -0.064 -0.066 -0.073 -0.087 -0.141 
𝑀𝑀𝑀𝑀𝑆𝑆(2)𝐸𝐸𝐵𝐵𝐸𝐸** -2.170 -2.173 -2.197 -2.229 -2.294 -2.516 -3.000 -4.875 
*Change in QALY gains required to maintain the level of utility when 1 unit of BOI is lost. 
** Change in QALY gains required to maintain the level of utility when moving from not being EOL to being EOL. 
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Table 7: Responses to the attitudinal questions 
 Normal life expectancy 5 20 40 80 All 
Question Response                                                                                             N 1022 760 889 998 3669 
 BOI      
1  The NHS should give priority to treating patients who are very ill 40.3% 41.7% 40.9% 40.2% 40.7% 
 The NHS should give the same priority to treating all patients who are ill, 
regardless of how ill they are 
59.7% 58.3% 59.1% 59.8% 59.3% 
2 The NHS should give priority to treating patients who are very ill and will die 
early because of their illness 
42.1% 41.6% 43.3% 42.8% 42.5% 
 The NHS should give the same priority to treating all patients who are ill, 
regardless of how ill they are or when they will die 
57.9% 58.4% 56.7% 57.2% 57.5% 
3 The NHS should always give priority to treating patients who are very ill and 
will die early because of their illness, even if they only get a small amount of 
benefit from treatment 
8.1% 9.9% 10.8% 9.6% 9.5% 
 The NHS should give priority to treating patients who are very ill and will die 
early because of their illness, but only if they get a large amount of benefit 
from treatment 
46.7% 44.5% 41.4% 44.7% 44.4% 
 The NHS should give the same priority to treating all patients, regardless of 
how ill they are or when they will die 
45.2% 45.7% 47.8% 45.7% 46.1% 
 EOL      
4 The NHS should give priority to extending the life of patients who are 
expected to die soon, even if this is the natural end of their life 
5.7% 6.8% 7.3% 5.5% 6.3% 
 The NHS should give priority to patients expected to die soon, but only if it 
means they die before the natural end of their life 
38.6% 38.0% 37.7% 39.1% 38.4% 
 The NHS should give the same priority to treating all patients, regardless of 
how ill they are or when they will die 
55.7% 55.1% 55.0% 55.4% 55.3% 
5 The NHS should give priority to extending the life of patients who are 
expected to die soon, even if this means they live in very poor health 
3.1% 4.3% 4.2% 4.0% 3.9% 
 The NHS should give priority to extending the life of patients who are 
expected to die soon, but only if they would live in a reasonable level of 
health 
56.2% 57.0% 56.9% 55.7% 56.4% 
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 Normal life expectancy 5 20 40 80 All 
 The NHS should give the same priority to treating all patients, regardless of 
how ill they are or when they will die 
40.7% 38.7% 38.9% 40.3% 39.7% 
7 The NHS should give priority to extending the life of patients expected to 
die soon 
11.8% 12.0% 13.8% 10.7% 12.0% 
 The NHS should give priority to treating patients who will get the largest 
amount of benefit from treatment 
88.2% 88.0% 86.2% 89.3% 88.0% 
 Therapeutic Improvement      
6 The NHS should give priority to treatments that give a large amount of 
benefit to a small number of patients 
8.8% 8.2% 8.9% 6.8% 8.1% 
 The NHS should give priority to treatments that give a small amount of 
benefit to a large number of patients 
8.3% 11.3% 10.6% 8.3% 9.5% 
 The NHS should consider the amount of benefit a treatment gives overall, 
rather than considering how it is shared out among different numbers of 
patients 
82.9% 80.5% 80.5% 84.9% 82.4% 
 Combined       
8 The NHS should give priority to treating patients who are very ill and will die 
early because of their illness 
9.3% 10.3% 12.8% 10.2% 10.6% 
 The NHS should give priority to treating patients who will get the largest 
amount of benefit from treatment 
47.2% 45.5% 43.0% 42.8% 44.6% 
 The NHS should give the same priority to treating all patients 43.5% 44.2% 44.2% 47.0% 44.8% 
9 The NHS should give priority to treating patients who are very ill and will die 
early because of their illness 
12.8% 12.6% 14.4% 12.4% 13.1% 
 The NHS should give priority to treating patients who will get the largest 
amount of benefit from treatment 
52.2% 53.8% 52.8% 50.3% 52.1% 
 The NHS should give priority to treating patients who will live for a long time 
and be in good health after treatment 
35.0% 33.6% 32.8% 37.3% 34.8% 
Note: Respondents were instructed to choose which of the grouped statements they agreed with most.   
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